梅輪電梯(603321.SH):擬與南寧軌道交通投資5億元建設年產能2.5萬台(套)電梯、自動扶梯整機及零部件等相關產品的生產基地
格隆匯8月1日丨c(603321.SH)公佈,2023年7月30日,公司第四屆董事會第二次會議審議通過了《關於擬對外投資暨簽署合作框架協議的議案》。同意公司本次對外投資事項並簽署合作框架協議,公司擬與南寧軌道交通集團有限責任公司合作在南寧建設年產能25,000台(套)電梯、自動扶梯整機及零部件等相關產品的生產基地,項目計劃總投資5億元,投資資金主要用於廠房建設、購置生產設備及經營流動資金。項目分二期建設,第一期擬投資30,000萬元、第二期擬投資20,000萬元,後續根據市場擴展情況考慮追加投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.